SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-24-014301 to Ainos, Inc. (AIMD, AIMDW) (CIK 0001014763) (AIMD)

Ainos, Inc. (AIMD, AIMDW) (CIK 0001014763)
Date: Dec. 27, 2024 · CIK: 0001014763 · Accession: 0000000000-24-014301

AI Filing Summary & Sentiment

File numbers found in text: 333-284003

Date
December 27, 2024
Author
Not clearly detected
Form
UPLOAD
Company
Ainos, Inc. (AIMD, AIMDW) (CIK 0001014763)

Letter

December 27, 2024 Chun-Hsien Tsai Chairman of the Board, President and Chief Executive Officer Ainos, Inc. 8880 Rio San Diego Drive, Ste. 800 San Diego, CA 92108 Re:Ainos, Inc. Registration Statement on Form S-3 Filed December 23, 2024 File No. 333-284003 Dear Chun-Hsien Tsai: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Steven Lipstein

Show Raw Text
December 27, 2024
Chun-Hsien Tsai
Chairman of the Board, President and Chief Executive Officer
Ainos, Inc.
8880 Rio San Diego Drive, Ste. 800
San Diego, CA 92108
Re:Ainos, Inc.
Registration Statement on Form S-3
Filed December 23, 2024
File No. 333-284003
Dear Chun-Hsien Tsai:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Tim Buchmiller at 202-551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Steven Lipstein